Avigen’s Argument With Largest Shareholder Emblematic Of Biotech Troubles
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotechnology Value Fund wants the firm to accept a merger offer from MediciNova; Avigen wants more time to keep rolling the dice.